This study concluded that breast cancer survivors who are on aromatase inhibitor therapy often experience GSM symptoms and sexual dysfunction, which negatively affects their quality of life. GSM assessment should be integrated into the care for breast cancer survivors. This evidence concerns the gene CYP19A1 and sexual dysfunction.